ALemtuzumab
Last Updated: 06/30/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 4211 publications
Targeting the cytokine storm: new therapies in the treatment of paediatric haemophagocytic lymphohistiocytosis.
Journal: Expert review of clinical immunology
Published: June 18, 2026
Targeting the cytokine storm: new therapies in the treatment of pediatric hemophagocytic lymphohistiocytosis.
Journal: Expert review of clinical immunology
Published: June 18, 2026
Biologics in Kidney Transplantation: Why and How Should We Personalize Their Dosage?
Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Published: May 25, 2026
Alemtuzumab-based HLA-haploidentical transplantation for relapsed/refractory aggressive NK-cell leukemia
Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology
Published: May 13, 2026
Patient‑Reported Satisfaction in Relapsing-Remitting Multiple Sclerosis: Advantages of At‑Home Self‑Administered Subcutaneous Ofatumumab Versus Other High‑Efficacy Therapies.
Journal: Drugs - real world outcomes
Published: April 06, 2026
First-in-Human Study of IL15-Activated Cytokine-Induced Killer Cells After Allogeneic HCT Shows Durable Remission and Serotherapy-Associated Immune Reconstitution in Leukemia.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: April 06, 2026
The impact of age on efficacy and safety of disease modifying treatment-insights from the Austrian Multiple Sclerosis Treatment Registry.
Journal: Journal of neurology
Published: March 14, 2026
Case Report: B-cell-targeted therapy with ofatumumab achieves remission in refractory panuveitis and coexisting multiple sclerosis.
Journal: Frontiers in neurology
Published: March 04, 2026
Efficacy and safety of monoclonal antibodies in the treatment of relapsing remitting multiple sclerosis: a systematic review.
Journal: Journal of neurology
Published: February 18, 2026
Violaceous Nodules on the Leg of an Alemtuzumab-Treated Kidney Transplant Recipient: Answer.
Journal: The American Journal of dermatopathology
Published: February 17, 2026
Violaceous Nodules on the Leg of an Alemtuzumab-Treated Kidney Transplant Recipient: Challenge.
Journal: The American Journal of dermatopathology
Published: February 17, 2026
Autologous stem cell transplantation (ASCT) for Refractory juvenile-onset systemic sclerosis (JSSc).
Autologous stem cell transplantation (ASCT) for Refractory juvenile-onset systemic sclerosis (JSSc).
Journal: Annals of the rheumatic diseases
Published: February 06, 2026
Last Updated: 06/30/2026